For the quarter ending 2025-09-30, AVNS had -$19,800K decrease in cash & cash equivalents over the period. $7,000K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -1,400 | -70,200 |
| Depreciation and amortization | 9,400 | 19,600 |
| Stock-based compensation expense | 3,500 | 7,900 |
| Goodwill impairment | 0 | 77,000 |
| Net loss on asset dispositions | -5,400 | -300 |
| Accounts receivable | -700 | -22,100 |
| Inventories | 500 | 2,100 |
| Prepaid expenses and other assets | 3,800 | -2,200 |
| Accounts payable | 1,100 | -1,600 |
| Accrued expenses | -400 | -22,000 |
| Deferred income taxes and other | 0 | -700 |
| Cash provided by operating activities | 14,000 | 32,500 |
| Capital expenditures | 7,000 | 17,700 |
| Proceeds from the sale of assets | 4,000 | - |
| Proceeds from rh divestiture post-closing settlement | 0 | 0 |
| Acquisition of assets and investments in businesses | -28,300 | - |
| Investments in non-affiliates | 200 | 4,600 |
| Cash used in investing activities | -31,500 | -22,300 |
| Secured debt repayments | 2,300 | 4,700 |
| Revolving credit facility proceeds | 0 | 0 |
| Revolving credit facility repayments | 0 | 25,000 |
| Purchases of treasury stock | 0 | 3,000 |
| Proceeds from the exercise of stock options | 300 | 400 |
| Payment of contingent consideration liabilities | 0 | 0 |
| Cash used in financing activities | -2,000 | -32,300 |
| Effect of exchange rate changes on cash and cash equivalents | -300 | 4,700 |
| (decrease) increase in cash and cash equivalents | -19,800 | -17,400 |
| Cash and cash equivalents at beginning of period | 107,700 | - |
| Cash and cash equivalents at end of period | 70,500 | - |
AVANOS MEDICAL, INC. (AVNS)
AVANOS MEDICAL, INC. (AVNS)